A case study of a patient with advanced, KRAS wild-type colorectal carcinoma, treated with cetuximab
2013
Abstract
Patients with metastatic colorectal carcinoma expressive the wild-type KRAS gene can profit more significantly from palliative chemotherapy, however in these patients specifically, the therapy can be made even more effective by adding anti-EGFR antibodies - cetuximab or panitumumab. In the presented case study, the therapy settings was based on the results of the following studies: CRYSTAL, OPUS, EPIC, NCIC CTC CO.17.